Cutaneous T-cell lymphomas (CTCLs) are a heterogenous group of non-Hodgkin lymphomas primarily involving the skin at diagnosis.2,3 The most common subtype of CTCL is mycosis fungoides (MF), followed by primary cutaneous anaplastic large cell lymphoma (pcALCL) and the much rarer subtype, Sezary syndrome (SS).3
Early-stage disease is mostly treated with skin-directed therapies; however, the chronic/relapsing nature of CTCL means that patients often require systemic therapies.4 Allogeneic stem cell transplantation is currently the only route to cure for patients with CTCL.4
In patients with CD30+ disease, brentuximab vedotin (BV) is now accepted by the SMC, and recommended by NICE and the UKCLG-BAD guidelines as an option in the UK for adult patients with CTCL who have received at least 1 prior systemic therapy, and have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome.1,5,6
During the pivotal Phase III study, BV delivered improved rates of durable response compared with physician’s choice – methotrexate or bexarotene which was consistent across subtypes* and CD30 expression (ORR4: 56.3% vs 12.5%; p<0.0001, respectively).7,8 BV demonstrated a generally manageable toxicity profile in CTCL.7
In the first case study, Professor Scarisbrick (University of Birmingham, UK) discusses one of her patients – a 48 year old male teacher who presented with pcALCL, who relapsed with nodal spread and was bridged to transplantation following treatment with BV. This patient has remained in complete remission since 2015.
*pcALCL and MF ORR = objective global response. ORR4 is calculated from the first response to the last response ≥4 months
In the second case study, Dr Osborne (Newcastle upon Tyne Hospitals NHS Foundation Trust, UK) discusses one of her patients – a 77 year old man who was diagnosed with MF, who had a symptomatic tongue lesion, and was treated with BV.
Click here for the GB or here for the NI prescribing information for ADCETRIS®▼(brentuximab vedotin) and details on reporting adverse events | Refer to the ADCETRIS UK Summaries of Product Characteristics (GB & NI) for full safety information1
ADCETRIS®▼(brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information.
1. ADCETRIS UK Summaries of Product Characteristics (GB & NI)
2. Gilson D et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019;180:496–526
3. Willemze R et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133(16):1703–1714
4. Brunner PM et al. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res 2020;9:F1000 Faculty Rev–331
5. National Institute of Clinical Excellence guidelines for brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
6. Scottish Medicines Consortium guidelines for brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
7. Prince HM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017;390(10094):555–566
8. Kim YH, et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician’s choice (PC) in the Phase 3 ALCANZA study. Abstract 7517. Presented at ASCO 2017, Chicago, IL.
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates